Sodium–glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline

AIMS/INTRODUCTION: Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of drugs for the treatment of type 2 diabetes mellitus that improve control of plasma glucose and bodyweight, giving great hope for the clinical utility of these agents. However, it is unclear for which patients SGL...

Descripción completa

Detalles Bibliográficos
Autores principales: Tobe, Kazuyuki, Suganami, Hideki, Kaku, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031493/
https://www.ncbi.nlm.nih.gov/pubmed/29032638
http://dx.doi.org/10.1111/jdi.12761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031493/
https://www.ncbi.nlm.nih.gov/pubmed/29032638
http://dx.doi.org/10.1111/jdi.12761

Ejemplares similares